These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7662991)

  • 1. Interleukin-12 inhibits murine graft-versus-host disease.
    Sykes M; Szot GL; Nguyen PL; Pearson DA
    Blood; 1995 Sep; 86(6):2429-38. PubMed ID: 7662991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells.
    Wang MG; Szebeni J; Pearson DA; Szot GL; Sykes M
    Transplantation; 1995 Sep; 60(5):481-90. PubMed ID: 7676498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion.
    Dey BR; Yang YG; Szot GL; Pearson DA; Sykes M
    Blood; 1998 May; 91(9):3315-22. PubMed ID: 9558388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.
    Aharoni R; Schlegel PG; Teitelbaum D; Roikhel-Karpov O; Chen Y; Arnon R; Sela M; Chao NJ
    Immunol Lett; 1997 Jul; 58(2):79-87. PubMed ID: 9271317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model.
    Yang YG; Dey B; Sergio JJ; Sykes M
    Transplantation; 1997 Nov; 64(9):1343-52. PubMed ID: 9371678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.
    Yang YG; Dey BR; Sergio JJ; Pearson DA; Sykes M
    J Clin Invest; 1998 Dec; 102(12):2126-35. PubMed ID: 9854048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD; Truitt RL
    Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
    Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
    J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD.
    Yang YG; Sykes M
    Leuk Lymphoma; 1999 May; 33(5-6):409-20. PubMed ID: 10342569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients.
    Sykes M; Pearson DA; Taylor PA; Szot GL; Goldman SJ; Blazar BR
    Biol Blood Marrow Transplant; 1999; 5(5):277-84. PubMed ID: 10534057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease.
    Zeng D; Lewis D; Dejbakhsh-Jones S; Lan F; García-Ojeda M; Sibley R; Strober S
    J Exp Med; 1999 Apr; 189(7):1073-81. PubMed ID: 10190898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strain dependence of interleukin-2-induced graft-versus-host disease protection: evidence that interleukin-2 inhibits selected CD4 functions.
    Sykes M; Harty MW; Pearson DA
    J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):11-21. PubMed ID: 8110726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.